文献速递血栓与止血白血病淋巴瘤

癌症相关血栓栓塞合并血小板减少症的抗凝治疗:前瞻性多中心队列研究

Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study.
PubMed 文献 · Blood Adv · 2021-01-01

该前瞻性多中心观察性研究纳入121例活动性恶性肿瘤、急性静脉血栓栓塞且血小板计数<100 000/µL的患者,比较全剂量与调整剂量抗凝。全剂量组60天大出血累积发生率为12.8%,调整剂量组为6.6%(Fine-Gray HR 2.18,95%CI 1.21-3.93);复发VTE分别为5.6%和0%。调整剂量抗凝可能是血小板减少症合并深静脉血栓癌症患者的安全替代方案。

要点

  • 全剂量抗凝组60天大出血累积发生率12.8%,调整剂量组6.6%。
  • 调整剂量抗凝组60天复发VTE为0%,全剂量组为5.6%。
  • 调整剂量抗凝者94%为血液恶性肿瘤,85%为急性深静脉血栓。

核心结论

  • 调整剂量抗凝可能是癌症合并血小板减少症患者发生深静脉血栓时治疗性抗凝的安全替代方案。

研究设计与样本

  • 前瞻性、多中心、观察性研究,纳入活动性恶性肿瘤、急性VTE且血小板计数<100 000/µL的患者。
  • 共121例患者入组于6家医院,主要结局经中心裁定,按初始全剂量或调整剂量抗凝进行比较。

主要发现

  • 接受调整剂量抗凝者中31/33(94%)为血液恶性肿瘤,28/33(85%)为急性深静脉血栓。
  • 全剂量抗凝组60天大出血累积发生率为12.8%(95%CI 4.9-20.8),调整剂量组为6.6%(95%CI 2.4-15.7),Fine-Gray HR 2.18(95%CI 1.21-3.93)。
  • 全剂量抗凝组60天复发VTE累积发生率为5.6%(95%CI 0.2-11),调整剂量组为0%。

临床怎么用

  • 对于癌症相关急性VTE合并血小板计数<100 000/µL的患者,可考虑调整剂量抗凝以降低大出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE) with concurrent thrombocytopenia is frequently encountered in patients with cancer. Therapeutic anticoagulation in the setting of thrombocytopenia is associated with a high risk of hemorrhage. Retrospective analyses suggest the utility of modified-dose anticoagulation in this population. To assess the incidence of hemorrhage or thrombosis according to anticoagulation strategy, we performed a prospective, multicenter, observational study. Patients with active malignancy, acute VTE, and concurrent thrombocytopenia (platelet count <100 000/µL) were enrolled. The cumulative incidences of hemorrhage or recurrent VTE were determined considering death as a competing risk. Primary outcomes were centrally adjudicated and comparisons made according to initial treatment with full-dose or modified-dose anticoagulation. A total of 121 patients were enrolled at 6 hospitals. Seventy-five patients were initially treated with full-dose anticoagulation (62%) and 33 (27%) with modified-dose anticoagulation; 13 (11%) patients received no anticoagulation. Most patients who received modified-dose anticoagulation had a hematologic malignancy (31 of 33 [94%]) and an acute deep vein thrombosis (28 of 33 [85%]). In patients who initially received full-dose anticoagulation, the cumulative incidence of major hemorrhage at 60 days was 12.8% (95% confidence interval [CI], 4.9-20.8) and 6.6% (95% CI, 2.4-15.7) in those who received modified-dose anticoagulation (Fine-Gray hazard ratio, 2.18; 95% CI, 1.21-3.93). The cumulative incidence of recurrent VTE at 60 days in patients who initially received full-dose anticoagulation was 5.6% (95% CI, 0.2-11) and 0% in patients who received modified-dose anticoagulation. In conclusion, modified-dose anticoagulation appears to be a safe alternative to therapeutic anticoagulation in patients with cancer who develop deep vein thrombosis in the setting of thrombocytopenia.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Carney BJ, Wang TF, Ren S, et al. Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study. Blood Adv. 2021. PMID: 34662892. doi:10.1182/bloodadvances.2021005966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。